OBJECTIVES:  This study was conducted to assess quality use of supportive care prescribed to patients on cancer chemotherapy. METHODS:  This was a prospective study conducted for a period of six months at private academic cancer care setting. Medical records of the patients on chemotherapy were reviewed and patients were interviewed during study period to study the use of supportive care. Evaluation of supportive care included reviewing quality use of anti-emetics, colony stimulating factors (CSF), analgesics, antibiotics and protein supplements. Quality use of supportive care was reviewed with respect to standard international recommendations and clinicians’ consensus of the study hospital. RESULTS:  A total of 850 patients were enrolled in this study. Majority patients on highly emetogenic regimen (48%) were prescribed with combination of metoclopramide and dexamethasone followed by combination of 5-HT3 antagonist and dexamethasone (46%). Use of neurokinin receptor antagonist was highly restricted (n=6%) due to unaffordability of patients. Only 144 (30%) of 480 patients who were on highly myelosuppressive chemotherapy were prescribed with prophylaxis of Filgrastim or Pegfilgrastim. CSF are not reimbursed for patients under government schemes and so its use was highly restricted (28 of 294 patients) despite of the need. Majority of the patients were prescribed with tramadol with or without non-steroidal analgesics (86%) for cancer related pain. Use of opioids like morphine was limited due to drug shortage at pharmacy. Fentanyl was used in limited patients due to financial constraints. Protein supplements were prescribed fairly (76%) for patients under private insurance whereas they were prescribed rarely (14%) for patients under government insurance schemes. CONCLUSIONS: Use of supportive care was not in well compliant with standard recommendations. Poor quality of supportive care delayed treatment schedules due to drug toxicities in our patients. Majority patients treated under government schemes had poor quality of supportive care compare to private patients.